Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.25 USD
Change Today +0.018 / 7.63%
Volume 316.1K
LPTN On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

lpath inc-class a (LPTN) Key Developments

Lpath Inc. - Special Call

To provide a corporate update and review data from the Nexus Phase 2 study that evaluated iSONEP as a treatment for patients with wet age-related macular degeneration

Lpath, Inc. to Present Nexus Phase 2 Study Data in Wet Age-Related Macular Degeneration At the 2015 American Academy of Ophthalmology Annual Meeting Retinal Subspecialty Day

Lpath Inc. announced that data from the Nexus Phase 2 study of iSONEP will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting Retina Subspecialty Day in Las Vegas, Nevada on November 14, 2015 at 12:59 p.m. Pacific Time. In May, Lpath announced that iSONEP did not meet the primary or key secondary endpoints in the Nexus trial, a prospective, randomized, Phase 2 clinical trial conducted in the U.S. that enrolled 158 patients with wet age-related macular degeneration (wet AMD) who had been subresponsive to treatment with existing anti-vascular endothelial growth factor (VEGF) therapies. Nexus trial patients did not show any statistically significant improvement in visual acuity at day 120 when treated with iSONEP as an adjunctive or monotherapy. Lpath conducted further analyses of the data including additional anatomical endpoints to better understand the results from each arm of the trial, and those findings will be included in the presentation at the AAO Annual Meeting.

Lpath Appoints Gary Atkinson Interim Chief Executive Officer

Lpath Inc. announced that Gary Atkinson has been appointed interim chief executive officer of Lpath, effective immediately. Mr. Atkinson will continue to serve as Lpath's chief financial officer. Mr. Atkinson joined Lpath as CFO in 2005, and has more than 20 years of experience with life science companies. Prior to Lpath, he served as the CFO for Quorex Pharmaceuticals, which was acquired by Pfizer. He also previously served as vice president of finance at Isis Pharmaceuticals, and as a financial consultant to Ichor Medical Systems. Earlier in his career, Mr. Atkinson served as the corporate controller at Loral Aerospace Corporation and as the director of financial planning at Cubic Corporation. Mr. Atkinson began his career at Ernst and Young. He is a graduate of Brigham Young University.

Lpath Inc. Initiates First-In-Human Dosing in Phase 1 Clinical Trial of Lpathomab

Lpath Inc. announced that the first cohort of six subjects has been dosed in the Phase 1 clinical trial with LpathomabTM. The double-blind, placebo-controlled, single ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Lpathomab in healthy volunteers. The trial also aims to establish a maximum tolerated dose for future clinical studies in patients with neuropathic pain. The trial will include a total of five cohorts at increasing doses. Lpathomab is an antibody targeting lysophosphatidic acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral adiculopathy. Other preclinical studies have also demonstrated the potential for Lpathomab as a treatment for traumatic brain injury.

Lpath Inc. Announces Plan to Begin Lpathomab Clinical Trial

Lpath Inc. announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application (IND) for Lpathomab. The FDA informed the company that the Phase 1 clinical trial to study Lpathomab may now be initiated. Lpath plans to begin this trial upon investigational review board approvals and anticipates the first subject to be dosed within two months.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPTN:US $0.25 USD +0.018

LPTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LPTN.
View Industry Companies

Industry Analysis


Industry Average

Valuation LPTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact LPATH INC-CLASS A, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at